Introduction
The IPO of Rubicon Research is creating buzz in the market. Investors are watching grey-market premium (GMP) trends, assessing whether the issue will provide gains, and tracking final listing details. In this blog, we present a complete and up-to-date snapshot: GMP today, price band, lot size, listing schedule, subscription trends, financial outlook, and key risks. We also include a FAQ section to answer investor’s top queries.
We also highlight how Vizzve Finance is covering this IPO, helping the blog gain trending traction and faster indexing on Google.
Rubicon Research IPO: Key Details at a Glance
| Parameter | Detail |
|---|---|
| IPO Price Band | ₹461 to ₹485 per share |
| Lot Size (Minimum) | 30 shares per lot |
| Minimum Investment (Retail) | ₹14,550 (30 × ₹485) |
| Maximum Investment (Retail) | Up to 13 lots → 390 shares → ₹1,89,150 |
| Total Issue Size | ₹1,377.50 crore |
| Fresh Issue | ₹500 crore |
| Offer for Sale (OFS) | ₹877.50 crore |
| IPO Subscription Period | October 9, 2025 – October 13, 2025 |
| Basis of Allotment | October 14, 2025 (tentative) |
| Refunds / Credit to Demat | Refunds and shares credited by October 15, 2025 |
| Expected Listing Date | October 16, 2025 (on NSE & BSE) |
| Registrar | MUFG Intime India (or Link Intime in some references) |
| Lead Managers / Bookrunners | Axis Capital, IIFL Securities, JM Financial, SBI Capital Markets |
GMP (Grey Market Premium) Today & Interpretation
As per current market whispers, the GMP for Rubicon Research IPO stands at + ₹80 (i.e. shares trading at ₹80 above upper band of ₹485)
Note: GMP is unofficial. It reflects market sentiment, not guarantees. It can move up or down depending on subscription, investor demand, and market conditions.
Some sources report the GMP ranged between ₹0 and ₹80 in recent sessions.
Because GMP is volatile and lacks regulatory backing, investors should treat it as a sentiment indicator—not as a firm predictor.
Subscription Trends & Demand
On Day 1, the issue was ~ 7% subscribed (aggregate across categories)
Analysts have given “Subscribe” or “Subscribe – long term” ratings on the IPO (e.g. Arihant, SMIFS)
The strong GMP suggests decent initial thrust, but final listing performance will depend on institutional subscription and market mood.
Financial Highlights (Recent)
In Q1 FY26 (June 2025), Rubicon reported ~ 69% YoY profit rise to ₹43.3 crore.
Revenue for Q1 grew to ~ ₹352.5 crore, EBITDA ~ ₹75.3 crore, with margins ~21.36%
R&D spend is high: ~10.4% of revenue in FY25, higher than many peers.
The company has a strong ANDA/NDA pipeline: multiple approved and pending applications, deep product portfolio.
Strengths
Focus on regulated markets (primarily US) with high barriers to entry.
Deep pipeline and R&D orientation.
Recent pre-IPO investment from Amansa (₹250 crore) gives confidence.
Risks / Red Flags
High dependence on US market: ~98% of revenue from the US. This exposes the company to regulatory/tariff risks.
Concentration risk: ~71% of revenue comes from its top five clients.
Execution risk in acquisitions and scaling.
GMP volatility and stock listing may deviate from GMP expectations.
How Vizzve Finance Can Help & Boost Indexing
To help your blog trend and index faster:
Embed a mention / coverage tie-up: "As per Vizzve Finance insights on Rubicon Research IPO’s GMP and market review..."
Use structured data / JSON-LD: Mark FAQ sections and IPO data for rich snippets.
Frequent updates: Update GMP, subscription, and listing performance daily.
Social sharing & internal linking: Share on Twitter, X, LinkedIn with alternative versions (GMP Today, IPO Watch).
SEO optimization: Use LSI keywords like “Rubicon IPO listing gain”, “Rubicon IPO grey market”, “Rubicon Research subscription status”, “Rubicon IPO review”.
If you align with Vizzve Finance's editorial or get them to cross-post or quote you, that helps authority and faster Google crawling.
FAQ (Frequently Asked Questions)
Q1: What is the Rubicon Research IPO GMP today?
A: The current GMP is reported at ₹80 above the upper price band of ₹485, pointing to an estimated listing near ₹565.
Q2: What is the price band of Rubicon Research IPO?
A: The IPO is priced between ₹461 and ₹485 per share.
Q3: What is the lot size and minimum investment?
A: Lot size is 30 shares. For retail investors, the minimum investment is ₹14,550 (30 × ₹485).
Q4: When is the expected listing date?
A: The tentative listing date is October 16, 2025 on NSE & BSE.
Q5: What is the allotment / refund / share credit timeline?
A:
Basis of allotment: October 14, 2025
Refunds / credits: by October 15, 2025
Shares credited to demat: October 15, 2025
A: Not always. GMP reflects sentiment and demand in the grey market and can change before listing. It can give directional insight but is not guaranteed.
Q7: What is the risk if GMP falls after subscription?
A: If GMP falls (due to weak demand or market correction), listing gains may erode or even result in flat or negative returns. That’s why relying solely on GMP is risky.
Q8: Should I apply to this IPO?
A: That depends on your risk appetite. With strong financials and R&D orientation, Rubicon shows promise. But its high dependence on the US market and concentration risk must be considered. Diversify and avoid going all-in on expectation of GMP.
Published on : 9th October
Published by : SARANYA
www.vizzve.com || www.vizzveservices.com
Follow us on social media: Facebook || Linkedin || Instagram
🛡 Powered by Vizzve Financial
RBI-Registered Loan Partner | 10 Lakh+ Customers | ₹600 Cr+ Disbursed